New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
04:55 EDTAZN, AZN, AZN, AZN, AZN, NVS, NVS, NVS, NVS, NVS, THLD, THLD, THLD, THLD, THLD, ABBV, ABBV, ABBV, ABBV, ABBV, RHHBY, RHHBY, RHHBY, RHHBY, RHHBY, JNJ, JNJ, JNJ, JNJ, JNJ, CLSN, CLSN, CLSN, CLSN, CLSN, PFE, PFE, PFE, PFE, PFE, NBS, NBS, NBS, NBS, NBS, INO, INO, INO, INO, INO, CLVS, CLVS, CLVS, CLVS, CLVS, BAYRY, BAYRY, BAYRY, BAYRY, BAYRY, BMY, BMY, BMY, BMY, BMY, MACK, MACK, MACK, MACK, MACKAmerican Society of Clinical Oncology to hold annual meeting
50th Annual Meeting of ASCO is being held in Chicago on May 30-June 3.
News For AZN;BMY;BAYRY;CLVS;INO;NBS;PFE;CLSN;JNJ;RHHBY;ABBV;THLD;NVS;MACK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
November 17, 2014
07:05 EDTTHLDThreshold Pharmaceuticals announces TH-302, bevacizumab Phase 1/2 interim data
Threshold Pharmaceuticals announced interim data from a U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab for the treatment of glioblastoma, or GBM, the most lethal form of brain cancer. All patients in the study had previously progressed on single-agent bevacizumab, the only FDA-approved therapy for GBM patients with progressive disease following prior therapy. As reported by the investigator, in a total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18%, and ten stable disease assessments for a clinical benefit rate of 64%; eight patients had progressive disease. Median progression-free survival was 2.8 months, and median overall survival was 4.6 months. In addition, the FDA, through its Office of Orphan Product Development, recently awarded Dr. Brenner a grant for a Phase 2 clinical trial of TH-302 for the treatment of GBM. His is one of 15 grants the FDA awarded in 2014 in order to boost the development of medical device, drug, and biological products for patients with rare diseases. According to the FDA, the grants are for clinical studies on safety and/or effectiveness of products that could either result in, or substantially contribute to, approval of the products.
06:43 EDTPFE, AZNAstraZeneca, Pfizer deal seen less likely after Merck transaction, Reuters says
Subscribe for More Information
05:30 EDTRHHBY, INOInovio, Roche terminate collaboration for INO-5150
Subscribe for More Information
05:27 EDTPFEPfizer lowers FY14 Reported EPS view to $1.40-$1.49 from $1.50-$1.59
Subscribe for More Information
05:23 EDTPFEPfizer forms strategic alliance with Merck KGaA
Subscribe for More Information
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
13:36 EDTAZNAstraZeneca presents data from studies of lesinurad combined with allopurinol
Subscribe for More Information
13:07 EDTBMYBristol-Myers announces results from CheckMate -066 study
Subscribe for More Information
November 14, 2014
17:27 EDTABBVPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:07 EDTABBVSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
16:51 EDTABBVAbbVie presents ABT-414 study, will initiate randomized phase 2 trial of ABT-414
Subscribe for More Information
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJ, ABBV, NVS, PFE, BMY, RHHBY, AZNCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:27 EDTRHHBYRoche reports FDA nod for Avastin in platinum-resistant recurrent ovarian cancer
Subscribe for More Information
12:08 EDTCLVSClovis November volatility elevated into update
Subscribe for More Information
10:00 EDTNBS, ABBVOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Deutsche Bank... Advance Auto Parts (AAP) initiated with a Buy at Sterne Agee... AutoZone (AZO) initiated with an Underperform at Sterne Agee... Carter's (CRI) initiated with a Buy at Sterne Agee... Children's Place (PLCE) initiated with a Neutral at Sterne Agee... Container Store (TCS) initiated with a Fair Value at CRT Capital... DHT Holdings (DHT) initiated with a Buy at UBS... Diana Shipping (DSX) initiated with a Neutral at UBS... Genuine Parts (GPC) initiated with a Neutral at Sterne Agee... National Oilwell (NOV) initiated with a Neutral at UBS... Navios Acquisition (NNA) initiated with a Buy at UBS... NeoStem (NBS) assumed with a Buy at Maxim... O'Reilly Automotive (ORLY) initiated with a Neutral at Sterne Agee... Scorpio Bulkers (SALT) initiated with a Neutral at UBS... Star Bulk Carriers (SBLK) initiated with a Neutral at UBS... Teekay Tankers (TNK) initiated with a Buy at UBS... The Buckle (BKE) initiated with an Underweight at BB&T... TriMas (TRS) initiated with an Overweight at JPMorgan... TriplePoint Venture (TPVG) initiated with a Buy at UBS... Tsakos Energy (TNP) initiated with a Buy at UBS... USD Partners (USDP) initiated with an Outperform at Credit Suisse... Zumiez (ZUMZ) initiated with a Buy at BB&T.
09:07 EDTNBSNeoStem assumed with a Buy at Maxim
Subscribe for More Information
07:14 EDTABBV, BMY, NVS, PFE, BAYRY, AZNAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
06:05 EDTBMYBristol-Myers to construct biologics manufacturing facility in Ireland
Subscribe for More Information
05:46 EDTABBVAbbVie initiated with a Buy at Deutsche Bank
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use